Drug Trial Radar · NCT06276556
Extension Study of ABP-671 in Participants With Gout
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
43
Actual
Start
Apr 22, 2024
Primary completion
Sep 5, 2024
Study completion Sep 5, 2024
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).
Conditions
- Gout
Interventions
ABP-671Drug
Participants who were randomized to any of the ABP-671 treatment groups in Part 1 or Part 2 of Study ABP-671-301 will continue to receive the same dose level and dosing regimen during the Treatment Period of this Extension Study. Participants who were randomized to receive placebo in Part 1 or Part 2 of Study ABP-671-301 will receive ABP-671 during the Treatment Period of the Extension Study.
AllopurinolDrug
Participants who were randomized to receive allopurinol in Part 1 of Study ABP-671-301 will continue to receive allopurinol during the Treatment Period of the Extension Study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve serum uric acid (sUA) levels <6.0 mg/dL (<0.360 mmol/L)Time frame: Week 26
- Incidence of treatment-emergent adverse events (Safety and Tolerability)Time frame: Week 26
Locations
54 sites in 5 countries. Site status is shown where the registry gives one.
Alliance for Multispecialty Research
Tempe, Arizona
Tucson Neuroscience Research, LLC
Tucson, Arizona
Anaheim Clinical Trials (Cenexel ACT)
Anaheim, California
Center for Clinical Trials of Sacramento
Sacramento, California
Access Research Institute
Brooksville, Florida
Nature Coast Clinical Reasearch
Crystal River, Florida
JY Research Institute Inc.
Cutler Bay, Florida
Accel Clinical Research Site
DeLand, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
A & D Doctor Center
Miami, Florida
Bioclinical Research Alliance
Miami, Florida
Cordova Research Institute
Miami, Florida
Century Research LLC
Miami, Florida
ITB Research
Miami, Florida
Combined Research Orlando Phase I-IV
Orlando, Florida
New Horizons Research
Palmetto Bay, Florida
Advanced Clinical Research of Atlanta
Atlanta, Georgia
Centricity Research
Columbus, Georgia
Alliance for Multispecialty Research, LLC.
Newton, Kansas
DelRicht Research
New Orleans, Louisiana
AMR
New Orleans, Louisiana
Annapolis Internal Medicine/CCT Research
Annapolis, Maryland
DelRicht Research of Gulfport
Gulfport, Mississippi
Quality Clinical Research, Inc
Omaha, Nebraska
Santa Rosa Medical Center
Las Vegas, Nevada
Inspire Santa Fe Medical Group
Santa Fe, New Mexico
OnSite Clinical Solutions
Salisbury, North Carolina
Altoona Center for Clinical Research
Duncansville, Pennsylvania
ClinSearch
Chattanooga, Tennessee
Medical Care/CCT
Elizabethton, Tennessee
PanAmerican Clinical Research, LLC
Brownsville, Texas
Quality Research Inc.
San Antonio, Texas
Worldwide Clinical Trials
San Antonio, Texas
Paratus Clinical Research Western Sydney
Blacktown, New South Wales, Australia
Emeritus Research Sydney
Botany, New South Wales, Australia
Paratus Clinical Research Central Coast
Kanwal, New South Wales, Australia
A R Houston Medical Pty Ltd
Kippa-Ring, Queensland, Australia
Emeritus Research Melbourne
Camberwell, Victoria, Australia
Austin Health - Repatriation Hospital
Heidelberg, Victoria, Australia
New Hospitals
Tbilisi, Georgia
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.